My attention - both as a practicing physician, diabetologist and endocrinologist, as well as a specialist in economics and health care - has been drawn for several months to the need to expand the reimbursement indications for semaglutide. Of course, this is all with the most important condition in mind - the health benefits for patients, as well as for the health care system. If someone is still wondering whether it is worth it, to gain conviction and get rid of doubts, just consider the beneficial effect of semaglutide on the overall health of Poles, including the reduction in the incidence of diseases related to obesity and type 2 diabetes. As for the use of the drug, my experience of more than two years with this still all time considered new drug is extremely positive.
Type 2 diabetes and obesity are chronic diseases that often coexist with each other, but also represent a growing health problem worldwide, including Poland, every year due to the increase in the number of cases. The negative consequences of these diseases are well known. Among the most common are: increased risk of cardiovascular disease, including strokes, kidney disease, neuropathy, as well as increased risk of developing certain cancers. All of us, doctors and even more so patients, are aware of the lower quality of life and shortened length of life in people suffering from obesity and type 2 diabetes, all of which translates into significant and ever-increasing costs to the health care system worldwide and to our society as a whole.
In this context, semaglutide (prep. Ozempic - used subcutaneously once a week or orally once a day - Rybelsus), dulaglutide (prep. Trulicity administered subcutaneously every 7 days) and other drugs that are, like the aforementioned GLP-1 analogs, are extremely promising tools in the fight against these serious health problems facing us as a society....
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
